Non-Erosive Gastroesophageal Reflux Disease (NERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Non-erosive reflux disease (NERD) represents a specific manifestation within the spectrum of gastroesophageal reflux disease (GERD). It is defined as a subcategory of GERD characterized by the presence of troublesome reflux-related symptoms, all the while showing no signs of mucosal erosions or breaches in the esophagus during routine endoscopy. In clinical practice, patients presenting with reflux symptoms and negative endoscopic findings can be further classified into four categories:
- Acid-reflux-related NERD (marked by increased acid reflux)
- Weakly acid-reflux-related NERD (exhibiting weakly acidic reflux with a positive symptom association, indicative of a hypersensitive esophagus)
- Nonacid-reflux-related NERD (characterized by nonacidic reflux with a positive symptom association)
- Functional heartburn (where no discernible link exists between symptoms and reflux)
Comparatively, NERD patients tend to experience lower levels of acid reflux than patients suffering from erosive esophagitis and Barrett's esophagus. The differentiation between NERD and erosive esophagitis currently relies on white light endoscopy. At the same time, the distinction between NERD and functional heartburn necessitates pH monitoring, often coupled with impedance measurements to gauge symptom-reflux associations. In general, it is noted that only around 20-30% of NERD patients respond positively to a standard dose of proton pump inhibitors (PPIs).
- In the United States, the estimated prevalence of GERD falls from 18.1% to 27.8%. Approximately half of all adults will report experiencing reflux symptoms at some point. Remarkably, NERD accounts for a significant proportion of all GERD cases, ranging from 50% to 85%.
Thelansis’s “Non-Erosive Gastroesophageal Reflux Disease (NERD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Erosive Gastroesophageal Reflux Disease (NERD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Non-Erosive Gastroesophageal Reflux Disease (NERD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Non-Erosive Gastroesophageal Reflux Disease (NERD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment